Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility
NCT ID: NCT00331370
Last Updated: 2006-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
2880 participants
INTERVENTIONAL
2006-05-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The role of the microcirculation is increasingly being recognized in the etiopathogenesis of cardiovascular disease. Delays in this recognition are in part due to the difficulty of studying the microcirculation non-invasively, in large numbers of individuals. Retinal vessels provide an easily accessible "window" to the microcirculation. Abnormalities of the retinal vasculature have been shown to be associated with cardiovascular risk factors and all cause mortality. Non-invasive assessment of the retinal circulation presents a valuable opportunity to study the structure and function of the microvasculature
Aims of the project
To compare geometry of retinal microvasculature of 1) hypertensive vs normotensive adults, 2) children aged 10 to 14 years of hypertensive parent (test group) versus normotensive parent (control group), and, 3) to assess the impact of blood pressure lowering on these changes over 2 years.
Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter ratios (a measure of relative arteriolar narrowing), b) narrowed branching angles (an indicator of arteriolar rarefaction), or c) disturbed junction exponents (a marker of endothelial dysfunction.
Significance of the study
If successful, this work could be extended to address future questions, including the predictive value of these abnormalities for development of diabetes and hypertension as well as CVD; to explore further the role of microvascular disturbances in disease etiology, and to assess the impact of drug therapy on these abnormalities and their relationship to outcomes in the South Asian population
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GP training and Health Education
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Those who have severe co-morbid conditions
Patients with known history of glaucoma will be excluded from our study because instillation of mydriatic drops was thought to be hazardous for them.
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Aga Khan University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tazeen H Jafar, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Aga Khan University
Nish Chaturvedi, MD, MFPHM
Role: STUDY_CHAIR
Imperial College London
Alun Hughes, MD, Phd
Role: STUDY_CHAIR
Imperial College London
Juanita Hatcher, Phd, MSc
Role: STUDY_CHAIR
Aga Khan University
Simon Thom, MD, FRCP
Role: STUDY_CHAIR
Imperial College London
Khabir Ahmad, MD, MSc
Role: STUDY_CHAIR
Aga Khan University
Muhammad Saleem Khan, MSc Epi&Bio
Role: STUDY_CHAIR
Aga Khan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aga Khan University
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tazeen H Jafar, MD, MPH
Role: primary
Muhammad Saleem Khan, MSc Epi&Bio
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DHCPP00493
Identifier Type: -
Identifier Source: org_study_id